Page 51 - Aet News Today

SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.

As IRA provisions are activated, the law’s impact on biologics and biosimilars will become more apparent. By using both the carrot and the stick, the IRA may finally bolster the market, increasing uptake of biosimilars to benefit patients and help lower costs.

COPD is the sixth leading cause of death—but more than 50% of those impacted don’t even have a diagnosis. The so-called silent epidemic demands urgent action, as exorbitant costs and preventable deaths skyrocket. This four-point plan outlines a holistic strategy to address COPD.

More precise and consumer-friendly biomarker detection technologies are coming to market at a pace that can help users gain rich insight into their health and well-being from anywhere and at any time. This is especially important when it comes to preventive healthcare.

By acquiring clinical assets from Wellory, Season Health will be able to greatly expand its provider network. The company will also gain national contracts with Aetna and Cigna.

Hospitals that are able to transform what they are and how they operate can survive and serve the public well. They will still require investments from society in the interim, but that investment will be justified by the public good and eventually represent a windfall to taxpayers.

CAR T-therapies for cancer are now under tighter FDA scrutiny as the agency opens an inquiry regarding reports that some patients who received these cell therapies went on to develop new cases of cancer. The FDA said benefits of these therapies still outweigh their risks, but it is evaluating the need for regulatory action.

Developed as part of the due diligence process for the disclosure of confidential documents, VDRs provide a secure repository for all types of confidential materials including merger and acquisition (M&A) documents, financial statements, contracts, intellectual property details, and legal agreements.

GSK took Blenrep off the market last year after the multiple myeloma drug failed its confirmatory study. But GSK now says it has interim data showing Blenrep beat a blockbuster Johnson & Johnson drug in a head-to-head Phase 3 study testing it as an earlier line of therapy.

As we navigate the complex terrain of virtual care integration, it is imperative to recognize the significance of payers as catalysts for change. By addressing the technological, procedural, and regulatory roadblocks head-on, payers can position themselves as champions of innovation and value